| Literature DB >> 32490228 |
Abstract
OBJECTIVE: To understand the microbial species, antimicrobial sensitivity and drug resistance of patients in the nursing hospital, to bring clinical guiding significance to the use of antimicrobial in the nursing hospital.Entities:
Keywords: Antimicrobial; Antimicrobial sensitivity; Drug resistance; Infectious disease; Microbial species; Nursing; Nursing hospital
Year: 2020 PMID: 32490228 PMCID: PMC7260137 DOI: 10.1016/j.heliyon.2020.e03965
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Total age distribution.
| Age range | Frequency | Constituent ratio |
|---|---|---|
| 100~110 | 20 | 1.66% |
| 90~99 | 255 | 21.21% |
| 80~89 | 578 | 48.09% |
| 70~79 | 223 | 18.55% |
| 60~69 | 110 | 9.15% |
| 50~59 | 14 | 1.16% |
| 40~49 | 2 | 0.17% |
| total | 1202 | 100.00% |
Distribution of specimens of major Gram-positive bacteria.
| Bacterial species | Bacterial name | type of sample | Constituent ratio |
|---|---|---|---|
| G+ | Enterococcus faecium | urine | 75.00% |
| G+ | Enterococcus faecium | blood-Aerobic | 16.67% |
| G+ | Enterococcus faecium | sputum | 8.33% |
| G+ | Staphylococcus haemolyticus | sputum | 47.62% |
| G+ | Staphylococcus haemolyticus | blood- Anaerobic | 19.05% |
| G+ | Staphylococcus haemolyticus | blood-Aerobic | 14.29% |
| G+ | Staphylococcus haemolyticus | Secretion | 9.52% |
| G+ | Staphylococcus haemolyticus | urine | 9.52% |
| G+ | Enterococcus faecalis | urine | 79.49% |
| G+ | Enterococcus faecalis | sputum | 15.38% |
| G+ | Enterococcus faecalis | Secretion | 5.13% |
| G+ | Staphylococcus epidermidis | sputum | 70.97% |
| G+ | Staphylococcus epidermidis | blood-Aerobic | 12.90% |
| G+ | Staphylococcus epidermidis | Secretion | 6.45% |
| G+ | Staphylococcus epidermidis | urine | 6.45% |
| G+ | Staphylococcus epidermidis | blood-Anaerobic | 3.23% |
| G+ | Staphylococcus aureus | sputum | 67.08% |
| G+ | Staphylococcus aureus | Secretion | 25.47% |
| G+ | Staphylococcus aureus | Decubitus Ulcers Secretion | 3.11% |
| G+ | Staphylococcus aureus | urine | 2.48% |
| G+ | Staphylococcus aureus | blood-Aerobic | 1.86% |
Distribution of specimens of major Gram-negative bacteria.
| Bacterial species | Bacterial name | type of sample | Constituent ratio |
|---|---|---|---|
| G- | E.coli | urine | 67.37% |
| G- | E.coli | sputum | 21.75% |
| G- | E.coli | Secretion | 3.86% |
| G- | E.coli | blood-Aerobic | 3.51% |
| G- | E.coli | blood-Anaerobic | 2.46% |
| G- | E.coli | Decubitus Ulcers Secretion | 1.05% |
| G- | Proteus mirabilis | urine | 94.29% |
| G- | Proteus mirabilis | Secretion | 2.86% |
| G- | Proteus mirabilis | sputum | 1.43% |
| G- | Proteus mirabilis | Decubitus Ulcers Secretion | 1.43% |
| G- | Klebsiella pneumoniae | sputum | 59.29% |
| G- | Klebsiella pneumoniae | urine | 33.63% |
| G- | Klebsiella pneumoniae | Secretion | 4.42% |
| G- | Klebsiella pneumoniae | Decubitus Ulcers Secretion | 1.77% |
| G- | Klebsiella pneumoniae | blood-Aerobic | 0.88% |
| G- | Pseudomonas aeruginosa | sputum | 75.45% |
| G- | Pseudomonas aeruginosa | urine | 12.57% |
| G- | Pseudomonas aeruginosa | Secretion | 9.58% |
| G- | Pseudomonas aeruginosa | Decubitus Ulcers Secretion | 2.40% |
| G- | Acinetobacter baumannii | sputum | 77.78% |
| G- | Acinetobacter baumannii | urine | 13.33% |
| G- | Acinetobacter baumannii | Decubitus Ulcers Secretion | 6.67% |
| G- | Acinetobacter baumannii | blood-Aerobic | 2.22% |
Distribution of major fungi.
| Bacterial species | Bacterial name | type of sample | Constituent ratio |
|---|---|---|---|
| Fungus | Candida glabrata | sputum | 69.23% |
| Fungus | Candida glabrata | urine | 15.38% |
| Fungus | Candida glabrata | Secretion | 7.69% |
| Fungus | Candida glabrata | stool | 7.69% |
| Fungus | Candida albicans | sputum | 88.89% |
| Fungus | Candida albicans | urine | 5.56% |
| Fungus | Candida albicans | stool | 1.85% |
| Fungus | Candida albicans | blood-Anaerobic | 1.85% |
| Fungus | Candida albicans | Secretion | 1.85% |
| Fungus | Dubliniensis Candida | sputum | 73.33% |
| Fungus | Dubliniensis Candida | urine | 20.00% |
| Fungus | Dubliniensis Candida | Secretion | 6.67% |
Gender distribution of several bacteria.
| Bacterial species | Bacterial name | gender | Frequency | Constituent ratio | χ2 |
|---|---|---|---|---|---|
| G+ | Enterococcus faecalis | female | 28 | 71.79% | 4.698∗ |
| G+ | Enterococcus faecalis | male | 11 | 28.21% | |
| G- | E.coli | female | 187 | 65.61% | 12.11∗∗ |
| G- | E.coli | male | 98 | 34.39% | |
| G- | Pseudomonas aeruginosa | male | 104 | 62.28% | 16.03∗∗ |
| G- | Pseudomonas aeruginosa | female | 63 | 37.72% |
∗P<0.05 ∗∗P<0.01.
Distribution of patient gender and specimen types.
| gender | type of sample | Frequency | Constituent ratio | gender | type of sample | Frequency | Constituent ratio | type of sample | Frequency | Constituent ratio |
|---|---|---|---|---|---|---|---|---|---|---|
| female | urine | 276 | 42.33% | male | urine | 156 | 28.36% | urine | 432 | 35.94% |
| female | sputum | 261 | 40.03% | male | sputum | 323 | 58.73% | sputum | 584 | 48.59% |
| female | Secretion | 70 | 10.74% | male | Secretion | 30 | 5.45% | Secretion | 100 | 8.32% |
| female | blood-Aerobic | 20 | 3.07% | male | blood-Aerobic | 18 | 3.27% | blood-Aerobic | 38 | 3.16% |
| female | blood-Anaerobic | 16 | 2.45% | male | blood-Anaerobic | 9 | 1.64% | blood-Anaerobic | 25 | 2.08% |
| female | Decubitus Ulcers Secretion | 8 | 1.23% | male | Decubitus Ulcers Secretion | 13 | 2.36% | Decubitus Ulcers Secretion | 21 | 1.75% |
| female | stool | 1 | 0.15% | male | stool | 1 | 0.18% | stool | 2 | 0.17% |
| total | 652 | 100.00% | total | 550 | 100.00% | total | 1202 | 100.00% | ||
Age distribution of Pseudomonas aeruginosa.
| Bacterial name | Age range | Frequency | Constituent ratio |
|---|---|---|---|
| Pseudomonas aeruginosa | 50~59 | 1 | 0.60% |
| Pseudomonas aeruginosa | 60~69 | 26 | 15.57% |
| Pseudomonas aeruginosa | 70~79 | 48 | 28.74% |
| Pseudomonas aeruginosa | 80~89 | 74 | 44.31% |
| Pseudomonas aeruginosa | 90~99 | 18 | 10.78% |
| total | 167 | 100.00% |
Antimicrobial sensitivity rate and resistance rate of Staphylococcus aureus (%).
| Bacterial name type | Staphylococcus aureus | Staphylococcus aureus | Staphylococcus aureus |
|---|---|---|---|
| I | R | S | |
| Gentamicin | 0(0) | 116(72.05) | 45(27.95) |
| Compound sulfamethoxazole | 0(0) | 27(16.77) | 134(83.23) |
| Levofloxacin | 0(0) | 145(90.06) | 16(9.94) |
| Clindamycin | 6(3.73) | 132(81.99) | 23(14.29) |
| Rifampin | 2(1.24) | 7(4.35) | 152(94.41) |
| Ergomycin | 2(1.24) | 138(85.71) | 21(13.04) |
| Vancomycin | 0(0) | 0(0) | 161(100) |
| penicillin | 0(0) | 156(96.89) | 5(3.11) |
| Linezolid | 0(0) | 0(0) | 161(100) |
| Koalaranin | 1(0.62) | 0(0) | 160(99.38) |
| Streptomycin | 2(1.25) | 18(11.25) | 140(87.5) |
Antimicrobial sensitivity rate and resistance rate of E.coli (%).
| Bacterial name type | E.coli | E.coli | E.coli |
|---|---|---|---|
| I | R | S | |
| Nitrofurantoin | 8(4.04) | 65(32.83) | 125(63.13) |
| Cefazolin | 5(1.77) | 238(84.1) | 40(14.13) |
| Gentamicin | 0(0) | 151(52.98) | 134(47.02) |
| Ampicillin | 1(0.35) | 262(92.25) | 21(7.39) |
| Cefuroxime | 1(0.35) | 223(79.08) | 58(20.57) |
| Ceftazidime | 13(14.29) | 47(51.65) | 31(34.07) |
| Cefepime | 38(13.43) | 149(52.65) | 96(33.92) |
| Cefoxitin | 12(4.35) | 95(34.42) | 169(61.23) |
| Ceftriaxone | 4(1.41) | 209(73.59) | 71(25) |
| Cefoperazone sulbactam | 40(14.08) | 32(11.27) | 212(74.65) |
| Piperacillin tazobactam | 15(5.28) | 44(15.49) | 225(79.23) |
| Ampicillin sulbactam | 48(16.9) | 126(44.37) | 110(38.73) |
| Meropenem | 4(1.41) | 35(12.32) | 245(86.27) |
| Imipenem | 7(2.46) | 35(12.32) | 242(85.21) |
| Amikacin | 7(2.46) | 26(9.15) | 251(88.38) |
| Compound sulfamethoxazole | 0(0) | 172(60.56) | 112(39.44) |
| Levofloxacin | 0(0) | 212(74.39) | 73(25.61) |
| Ciprofloxacin | 4(1.4) | 211(74.04) | 70(24.56) |
| Minocycline | 32(11.23) | 68(23.86) | 185(64.91) |
Antimicrobial sensitivity rate and resistance rate of Proteus mirabilis (%).
| Bacterial name type | Proteus mirabilis | Proteus mirabilis | Proteus mirabilis |
|---|---|---|---|
| I | R | S | |
| Nitrofurantoin | 0(0) | 64(100) | 0(0) |
| Cefazolin | 3(4.29) | 53(75.71) | 14(20) |
| Gentamicin | 3(4.29) | 53(75.71) | 14(20) |
| Ampicillin | 0(0) | 63(90) | 7(10) |
| Cefuroxime | 1(1.45) | 47(68.12) | 21(30.43) |
| Ceftazidime | 6(23.08) | 6(23.08) | 14(53.85) |
| Cefepime | 16(22.86) | 23(32.86) | 31(44.29) |
| Cefoxitin | 3(4.29) | 10(14.29) | 57(81.43) |
| Ceftriaxone | 1(1.45) | 40(57.97) | 28(40.58) |
| Cefoperazone sulbactam | 0(0) | 2(2.86) | 68(97.14) |
| Piperacillin tazobactam | 0(0) | 2(2.86) | 68(97.14) |
| Ampicillin sulbactam | 9(12.86) | 30(42.86) | 31(44.29) |
| Meropenem | 0(0) | 3(4.35) | 66(95.65) |
| Imipenem | 8(11.43) | 3(4.29) | 59(84.29) |
| Amikacin | 3(4.29) | 11(15.71) | 56(80) |
| Compound sulfamethoxazole | 0(0) | 61(88.41) | 8(11.59) |
| Levofloxacin | 1(1.43) | 58(82.86) | 11(15.71) |
| Ciprofloxacin | 2(2.86) | 58(82.86) | 10(14.29) |
| Minocycline | 1(1.43) | 69(98.57) | 0(0) |
Antimicrobial sensitivity rate and resistance rate of Klebsiella pneumoniae (%).
| Bacterial name type | Klebsiella pneumoniae | Klebsiella pneumoniae | Klebsiella pneumoniae |
|---|---|---|---|
| I | R | S | |
| Nitrofurantoin | 5(13.51) | 21(56.76) | 11(29.73) |
| Cefazolin | 2(1.79) | 97(86.61) | 13(11.61) |
| Gentamicin | 0(0) | 74(65.49) | 39(34.51) |
| Ampicillin | 0(0) | 106(99.07) | 1(0.93) |
| Cefuroxime | 0(0) | 91(81.98) | 20(18.02) |
| Ceftazidime | 1(3.23) | 21(67.74) | 9(29.03) |
| Cefepime | 12(10.91) | 64(58.18) | 34(30.91) |
| Cefoxitin | 3(2.78) | 71(65.74) | 34(31.48) |
| Ceftriaxone | 1(0.91) | 83(75.45) | 26(23.64) |
| Cefoperazone sulbactam | 8(7.14) | 48(42.86) | 56(50) |
| Piperacillin tazobactam | 9(8.11) | 50(45.05) | 52(46.85) |
| Ampicillin sulbactam | 7(6.31) | 78(70.27) | 26(23.42) |
| Meropenem | 1(0.89) | 46(41.07) | 65(58.04) |
| Imipenem | 5(4.46) | 47(41.96) | 60(53.57) |
| Amikacin | 0(0) | 38(33.93) | 74(66.07) |
| Compound sulfamethoxazole | 0(0) | 71(63.96) | 40(36.04) |
| Levofloxacin | 5(4.46) | 78(69.64) | 29(25.89) |
| Ciprofloxacin | 5(4.59) | 80(73.39) | 24(22.02) |
| Minocycline | 31(28.7) | 26(24.07) | 51(47.22) |
Antimicrobial sensitivity rate and resistance rate of Pseudomonas aeruginosa (%).
| Bacterial name type | Pseudomonas aeruginosa | Pseudomonas aeruginosa | Pseudomonas aeruginosa |
|---|---|---|---|
| I | R | S | |
| Gentamicin | 3(1.8) | 72(43.11) | 92(55.09) |
| Ceftazidime | 10(6.02) | 51(30.72) | 105(63.25) |
| Cefepime | 19(11.38) | 37(22.16) | 111(66.47) |
| Cefoperazone sulbactam | 34(20.36) | 33(19.76) | 100(59.88) |
| Piperacillin tazobactam | 28(16.87) | 41(24.7) | 97(58.43) |
| Meropenem | 8(4.79) | 56(33.53) | 103(61.68) |
| Imipenem | 3(1.8) | 62(37.13) | 102(61.08) |
| Amikacin | 10(5.99) | 34(20.36) | 123(73.65) |
| Levofloxacin | 4(2.4) | 92(55.09) | 71(42.51) |
| Ciprofloxacin | 6(3.59) | 93(55.69) | 68(40.72) |
| Piperacillin | 25(14.97) | 57(34.13) | 85(50.9) |
| Tobramycin | 3(1.8) | 65(38.92) | 99(59.28) |
| Aztreonam | 36(21.56) | 68(40.72) | 63(37.72) |
| Polymyxin B | 2(1.2) | 4(2.4) | 161(96.41) |
| Tigecycline | 0(0) | 0(0) | 161(100) |
Antimicrobial sensitivity rate and resistance rate of Candida glabrata (%).
| Bacterial name type | Candida glabrata | Candida glabrata | Candida glabrata |
|---|---|---|---|
| I | R | S | |
| Fluorocytosine | 0(0) | 9(69.23) | 4(30.77) |
| Amphotericin B | 0(0) | 2(15.38) | 11(84.62) |
| Fluconazole | 1(7.69) | 4(30.77) | 8(61.54) |
| Itraconazole | 2(15.38) | 2(15.38) | 9(69.23) |
| Voriconazole | 0(0) | 1(7.69) | 12(92.31) |